Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

Clinical trial to investigate the adherence of a new Rotigotine patch to the skin of patients with Parkinson’s disease Ended

2025-521172-64-00 Parkinson's disease 4 2026-01-05
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended

2025-521107-42-00 Alzheimer's Disease 4 2025-11-25
A Phase 1, Multi-Cohort, Open-Label, Randomized Pilot Study to Evaluate the Effect of Food and a Proton-Pump Inhibitor (esomeprazole) on the… Ended

2025-523370-16-00 Parkinsonian syndromes 3 2025-11-17
A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of … Ended

2025-522287-32-00 Depression 3 2025-10-22
A PHASE 1, OPENLABEL, SINGLECENTER STUDY TO EVALUATE DRUGDRUG INTERACTIONS WITH GEMFIBROZIL, ITRACONAZOLE, AND CARBAMAZEPINE AND THE FOOD-EF… Ended

2025-521508-23-00 Adrenoleukodystrophy 3 2025-10-10
Treatment of normal pressure hydrocephalus with acetazolamide Ended

2024-514828-16-00 Normal pressure hydrocephalus 4 2025-09-25
Research into new test methods to measure pain with two existing drugs (nefopam and oxycodone) Ended

2025-522389-66-00 (Chronic) pain 3 2025-09-24
A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combi… Ended

2025-521754-41-00 Multiple sclerosis 3 2025-08-15
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune D… Ended

2024-518797-13-00 systemic lupus erythematosus [SLE]/lupus nephritis [LN] 3 2025-07-10
A Study to Learn How Safe Different Doses of NTS-521 are, What the Amount of NTS-521 in the Body is Over a Period of Time, and What the Effe… Ended

2024-518613-26-01 Not applicable 1 2025-06-06
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended

2024-513435-24-01 Neuropathic Pain; Distal Sensory Polyneuropathy 4 2025-06-03
A clinical study of MK-6916 in healthy people (MK-6916-006) Ended

2025-521487-36-00 Acute and chronic Pain 3 2025-06-02
Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP Ended

2024-515386-34-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-05-29
Bioavailability study of stiripentol after single oral administration of two different formulations (capsule and oral suspension) in 24 heal… Ended

2024-520103-38-00 Dravet syndrome 3 2025-05-26
A randomised, assessor-blinded, controlled, healthy volunteer, Phase I study to assess skin irritation and sensitization potential of a nove… Ended

2024-518038-10-00 None. Healthy subjects 3 2025-05-12
A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP Ended

2024-518364-12-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-05-09
Drug-Drug Interaction Study With BIA 28-6156 and Clarithromycin, Midazolam, and Dabigatran Etexilate in Healthy Participants Ended

2025-520840-14-00 Healthy volunteers 3 2025-04-29
Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulatio… Ended

2025-520980-41-00 narcolepsy with cataplexy 3 2025-04-08
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 Ended

2024-515452-20-00 Narcolepsy Type 2 4 2025-04-01
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Th… Ended

2024-515539-31-00 Alzheimer’s disease dementia 4 2025-04-01
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharma… Ended

2023-506723-28-00 Mitochondrial encephalomyopathy, lactic acidosis and st 4 2025-03-20
A study to investigate safety, tolerability, pharmacokinetics and efficacy of REM0045392 compared with placebo in healthy participants Ended

2025-520454-11-00 Alzheimer 1 2025-03-20
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivara… Ended

2024-516500-42-00 Epilepsy 2 2025-03-13
The rimegePant in RElation to obeSiTy in mIGrainE study Ended

2024-513359-34-00 Obesity 6 2025-03-10